Smart chemo strategy aims to outsmart pancreatic cancer recurrence
NCT ID NCT07044453
First seen Feb 20, 2026 · Last updated May 14, 2026 · Updated 15 times
Summary
This study tests whether giving different types of chemotherapy after surgery, based on how much the tumor shrank with initial chemo, can help prevent pancreatic cancer from coming back. About 390 adults who had surgery after 3 months of a specific chemo (mFOLFIRINOX) will be assigned to either standard or adjusted chemo. The goal is to improve survival and reduce side effects by tailoring treatment to each person's tumor response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESECTED PANCREATIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
CHU de Rouen
RECRUITINGRouen, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.